InspireMD, Inc. Q2 2026 Earnings Call Summary

InspireMD, Inc.'s Q2 2026 earnings call revealed flat revenue due to a voluntary recall of the CGuard Prime 135 system, which required $734,000 in customer credits. International sales grew by 21%, demonstrating the clinical efficacy and physician demand for the CGuard implant. To align with regulatory priorities, the company reduced its workforce by 20%, aiming to conserve cash while maintaining a lean commercial core.

The CGuard implant remains the primary value driver, and the recall was isolated to the delivery system. Management expects potential FDA approval for CGuard Prime 80 (TCAR) and CGuard CAS in Q4 2026. A redesigned CGuard Prime 135 delivery system is targeted for reentry in H2 2027. The company anticipates $9 million in annual cost-saving benefits by Q4 2026.

SwitchGuard, a neuroprotection system, is expected to receive U.S. approval in the back-half of 2027. The voluntary recall led to a $612,000 impairment charge for CGuard Prime 135 inventory deemed non-viable. A restructuring charge between $900,000 and $1.2 million is expected in Q3 2026 to cover severance costs. Gross margin was negative 43.7%, but adjusted gross profit remained positive at $0.6 million.

The company is focusing on margin expansion, pricing optimization, and a dual-track U.S. strategy, preparing to address the entire 75,000-procedure stenting market with both TCAR and CAS platforms.